Cooper Companies (NASDAQ:COO) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Cooper Companies (NASDAQ:COO) announced its quarterly earnings data on Wednesday. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.03, Zacks reports. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. Cooper Companies updated its Q4 2026 guidance to 1.050-1.090 EPS and its FY 2026 guidance to 4.510-4.550 EPS.

Cooper Companies Stock Performance

NASDAQ COO traded down $4.21 during trading on Wednesday, hitting $63.48. 8,383,881 shares of the company’s stock traded hands, compared to its average volume of 2,347,124. The stock has a market capitalization of $12.38 billion, a price-to-earnings ratio of 53.80, a PEG ratio of 1.82 and a beta of 0.82. Cooper Companies has a 12-month low of $58.89 and a 12-month high of $89.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The business has a 50 day moving average of $72.59 and a 200-day moving average of $70.17.

Institutional Trading of Cooper Companies

Several hedge funds and other institutional investors have recently modified their holdings of COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Cooper Companies by 48.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after buying an additional 7,363 shares in the last quarter. First Trust Advisors LP raised its holdings in Cooper Companies by 115.8% during the 2nd quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock valued at $9,702,000 after acquiring an additional 73,165 shares during the period. Cresset Asset Management LLC purchased a new stake in shares of Cooper Companies during the second quarter worth $291,000. Cerity Partners LLC boosted its holdings in shares of Cooper Companies by 4.4% in the second quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock worth $1,272,000 after acquiring an additional 757 shares during the period. Finally, Daiwa Securities Group Inc. increased its holdings in shares of Cooper Companies by 2.8% in the second quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock worth $2,551,000 after buying an additional 973 shares during the period. Institutional investors own 24.39% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on COO shares. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. The Goldman Sachs Group set a $61.00 target price on Cooper Companies in a report on Wednesday, May 27th. JPMorgan Chase & Co. reduced their price target on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a research report on Friday, June 5th. Piper Sandler set a $86.00 price objective on shares of Cooper Companies and gave the stock an “overweight” rating in a report on Monday, June 1st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Cooper Companies in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Cooper Companies has an average rating of “Hold” and an average target price of $81.64.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies increased its share-repurchase authorization from $2 billion to $3 billion. The larger buyback could support earnings per share and signal that management views the stock as undervalued. The company also said its board remains open to other value-creation options. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: CooperCompanies completed its strategic review and unanimously decided to retain CooperSurgical. While the decision removes uncertainty around the business, it also means the company will not receive a potential near-term cash infusion from a sale or separation. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: The company released fiscal third-quarter 2026 results for the period ended July 31. The supplied announcement does not include the reported revenue or earnings figures, so the market’s reaction is likely being driven primarily by the forward guidance. CooperCompanies Announces Third Quarter 2026 Results
• Negative Sentiment: Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 is below the consensus estimate of $4.63. Revenue guidance of $4.2–$4.3 billion is also below or only reaches the $4.3 billion consensus at the high end, suggesting weaker-than-expected growth or profitability.
• Negative Sentiment: Fourth-quarter 2026 EPS guidance of $1.05–$1.09 is well below the $1.20 consensus estimate. Although revenue guidance of approximately $1.1 billion is broadly in line with expectations, the earnings shortfall indicates pressure on margins, costs, or the business mix.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.